Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942708 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00942708: Completed Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT00942708 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00942708, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for three months among patients with pulmonary arterial hypertension.
Primary Outcome
PVR will be measured by right heart catheterization at baseline and 3 months. Change in PVR will be determined by baseline value minus 3 month value.
Interventions
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
What the finished NCT00942708 record still lists
NCT00942708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Fluoxetine is the first listed.
NCT00942708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00942708 about?
NCT00942708 is a clinical study titled "Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension". This study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for three months among patients with pulmonary arterial hypertension.
What is the current status of trial NCT00942708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2009-09. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00942708?
The interventions under investigation include: Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00942708?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00942708's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia